Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017

Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine

M. Joannidis1*, W. Druml2, L. G. Forni3, A. B. J. Groeneveld, P. M. Honore4, E. Hoste5, M. Ostermann6, H. M. Oudemans-van Straaten7 and M. Schetz8

© 2017 The Author(s). This article is an open access publication

Abstract

Background: Acute kidney injury (AKI) in the intensive care unit is associated with significant mortality and morbidity.

Objectives: To determine and update previous recommendations for the prevention of AKI, specifically the role of fluids, diuretics, inotropes, vasopressors/vasodilators, hormonal and nutritional interventions, sedatives, statins, remote ischaemic preconditioning and care bundles.

Method: A systematic search of the literature was performed for studies published between 1966 and March 2017 using these potential protective strategies in adult patients at risk of AKI. The following clinical conditions were considered: major surgery, critical illness, sepsis, shock, exposure to potentially nephrotoxic drugs and radiocontrast. Clinical endpoints included incidence or grade of AKI, the need for renal replacement therapy and mortality. Studies were graded according to the international GRADE system.

Results: We formulated 12 recommendations, 13 suggestions and seven best practice statements. The few strong recommendations with high-level evidence are mostly against the intervention in question (starches, low-dose dopamine, statins in cardiac surgery). Strong recommendations with lower-level evidence include controlled fluid resuscitation with crystalloids, avoiding fluid overload, titration of norepinephrine to a target MAP of 65–70 mmHg (unless chronic hypertension) and not using diuretics or levosimendan for kidney protection solely.

Conclusion: The results of recent randomised controlled trials have allowed the formulation of new recommendations and/or increase the strength of previous recommendations. On the other hand, in many domains the available evidence remains insufficient, resulting from the limited quality of the clinical trials and the poor reporting of kidney outcomes.

*Correspondence: michael.joannidis@i-med.ac.at
1 Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstasse 35, 6020 Innsbruck, Austria
Full author information is available at the end of the article

Professor Groeneveld succumbed to a long illness which he fought with typical determination during the updating of this paper. He is sadly missed by us all.
Introduction
Acute kidney injury (AKI) affects up to 50% of critically ill patients and is independently associated with both short- and long-term morbidity and mortality [1–5]. The recent AKI-EPI study demonstrates that the most frequent causes of AKI in the critically ill are sepsis and hypovolaemia followed by nephrotoxic agents [6]. However, the cause of AKI is often multifactorial with pre-existing co-morbidities further increasing the risk [3, 7–9].

The aim of this systematic review on the prevention and avoidance of further progression of AKI, by core members of the AKI section of the ESICM, is to provide:

• A critical evaluation of the existing evidence
• Give recommendations for clinical practice
• Update our previously published recommendations [10] and most recent guidelines [2, 11]

Our recommendations principally concern critically ill patients on the ICU but can also be applied to those planned to be admitted to the ICU such as high-risk surgical patients. By consensus, we primarily focussed on the role of volume expansion, diuretics, inotropes, vasopressors/vasodilators, hormones, nutrition, statins, sedatives and ischaemic preconditioning.

Methodology
A systematic search of the literature was performed using the following databases: MEDLINE (1966 through March 2017), EMBASE (1980 through March 2017), CINAHL (1982 through March 2017), Web of Science (1955 through March 2017) and PubMed/ PubMed CENTRAL to identify key studies, preferably randomised (placebo) controlled trials (RCT) and meta-analyses, addressing strategies to prevent AKI in adult critically ill patients. The following clinical conditions were considered: major surgery, critical illness, sepsis, shock and exposure to potentially nephrotoxic drugs. Specifically, renal transplantation, primary intrinsic renal disease (e.g. vasculitis) and hepatorenal syndrome were not considered. Search strategy and endpoints are available as electronic supplementary material (ESM_1).

These recommendations are intended to provide clinical guidance and involved a modified Delphi process with a consensus meeting during the annual congresses of the European Society of Intensive Care Medicine in 2014, 2015 and 2016 followed by electronic-based/telephone discussions. The quality of the evidence was judged by using the most recent GRADE (Gradings of Recommendations, Assessment, Development and Evaluation) criteria (Fig. 1) [12, 13]. The strength of the recommendations was classified as either strong (Grade 1) or weak (Grade 2). The degree (i.e. quality) of evidence for the recommendations was classified from high (A) to very low (D) according to factors including study design consistency of the results and directness of the evidence (Fig. 1, ESM_1 Table S1). Evidence was downgraded where there was a risk of bias, inconsistency and imprecision. Evidence was upgraded for large effect size or significant dose–response gradient. If benefit or harm was unequivocal, but evidence was difficult to categorize by the GRADE methodology, we used best practice statements (BPSs), which represent ungraded strong recommendations [14] (Table 1).

We acknowledge that there may be circumstances whereby a recommendation cannot or should not be followed for an individual patient. Furthermore, interventions are generally investigated in isolation and not in combination, and as such recommendations relate to the primary intervention. Local clinical guidelines will govern the use of either a single intervention or a combination thereof.
Volume expansion

Recommendations

1. We recommend controlled fluid resuscitation in volume depletion, while, however, avoiding volume overload (Grade 1C).
2. We recommend against the use of starches (Grade 1A) as harm has been shown and suggest not using gelatine or dextrans for fluid resuscitation (Grade 2C).
3. We recommend correction of hypovolaemia dehydration using isotonic crystalloids in patients receiving intravascular contrast media (Grade 1B).
4. We recommend regular monitoring of chloride levels and acid–base status in situations where chloride-rich solutions are used (BPS).
5. We suggest the use of balanced crystalloids for large volume resuscitation (Grade 2C).
6. We suggest using human serum albumin if a colloid is deemed necessary for the treatment of patients with septic shock (Grade 2C).
7. We suggest prophylactic volume expansion with crystalloids to prevent AKI by certain drugs (specified below) (BPS).
8. We suggest not delaying urgent contrast-enhanced investigations or interventions for potential preventative measures (BPS).

Rationale

Relative and overt hypovolaemia are significant risk factors for development of AKI [15–18]. Timely fluid administration can restore circulating volume and renal perfusion, and may also reduce nephrotoxicity [19]. Volume replacement should be performed in a controlled, monitored fashion [20] as injudicious use of fluids carries its own inherent risks and may even contribute to AKI by increasing renal interstitial oedema and renal parenchymal pressure [21, 22]. Moreover, goal-directed therapy including the use of central venous pressure (CVP) as a resuscitation target has not been shown to prevent AKI in sepsis [23]. Volume replacement may be through crystalloids, colloid, or their combination. Isotonic crystalloids represent the mainstay for correcting extracellular volume depletion with the caveat that hyperchloraemia is prevented to reduce potential renal vasoconstriction [24, 25]. Compared to crystalloids, colloids theoretically result in a greater plasma expansion. However, this effect depends on vascular barrier integrity which may be compromised in sepsis, particularly in the presence of vasoplegia [26, 27]. Consequently, the difference in required volumes for fluid resuscitation was minimal between crystalloids and colloids in large RCTs [28]. Moreover, large volume replacement with colloids alone risks hyperoncotic impairment of glomerular filtration [29, 30] and osmotic tubular damage [31, 32].

Available artificial colloids include gelatines, dextrans and until recently, starches. Gelatines have a moderate volume effect. Although risk of osmotic nephrosis with gelatines exists [33], the lack of clear clinical data on deleterious effects on renal function [34, 35] is offset by the possible prion transmission, histamine release and coagulopathy [36, 37]. Dextrans have reasonably high volume effects although anaphylaxis, coagulation disorders, osmotic nephrosis and AKI may occur with doses above 1.5 g/kg/day [38–41]. Human albumin (HA) is the only naturally occurring colloid and may appear attractive in hypooncotic hypovolaemia. It does increase the response to diuretics in patients with hypoaalbuminaemia (e.g. nephrotic syndrome) [42, 43], has no negative effects on kidney function [44, 45], is safe [46] but can be costly.

Clinical studies

Unsurprisingly, no studies have specifically addressed the effects of volume expansion compared to no volume resuscitation in overt hypovolaemia given the intuitive benefits of volume replacement. In severe sepsis, the beneficial effects of timely volume replacement on organ failure and mortality are well known, although the first RCT proving benefit of early volume resuscitation did not report kidney function [47]. On the other hand, preoperative volume expansion failed to reduce the incidence of postoperative AKI in 328 patients undergoing cardiac surgery [48], and a recent pilot RCT in sepsis could demonstrate that a volume-restrictive fluid protocol can reduce the incidence of AKI (RR 0.32; 95% CI 0.32–0.96) [49].

Crystalloids are considered the mainstay for volume expansion. Observational studies suggest an increased risk of AKI, renal replacement therapy (RRT) and mortality associated with the use of large volumes of normal saline (0.9% NaCl) as compared to so-called balanced solutions where chloride is partially replaced by another metabolizable anion [50–52]. An RCT comparing saline to a balanced solution (Plasmalyte®) in 2278 patients treated in four ICUs failed to show any superiority of balanced crystalloids regarding renal outcomes [53]. The study has been criticized for the limited fluid doses, inclusion of patients with low disease severity and the absence of data on chloride levels [54]. Similar results were observed in the pilot cluster-randomised, multiple-crossover SALT trial comparing saline to a balanced solution in 974 critically ill adults [55]. Again, only modest volumes were used, but increased rates of AKI were found in the normal saline group if larger volumes were administered (ESM_2 Table S2). Studies on the effectiveness of sodium bicarbonate in preventing AKI, predominantly in patients undergoing cardiac surgery, have produced
conflicting results [56–59] as have consecutive meta-analyses [60–63].

The effect of colloids on renal function has undergone extensive scrutiny over the last decade. Large RCTs have substantiated the increased risk of AKI and RRT with use of starches [64] particularly in sepsis [65, 66], where they also lead to increased mortality [66] (ESM_2 Table S3). This is verified by several meta-analyses [67–70] which underpin the abandoning of starches in critically ill patients [20, 71, 72]. Clinical data on the effects of gelatine on renal function are scarce. A recent meta-analysis, including three trials in 212 patients comparing gelatins with crystalloids or albumin, indicated a 35% increased relative risk of developing AKI with gelatine [73].

In contrast to artificial colloids, the administration of albumin appears to be safe for the kidney. A large RCT comparing normal saline to 4% HA in various clinical settings failed to demonstrate any differences in renal function [46] (ESM_2 Table S3). In the ALBIOS trial the use of hyperoncotic (20%) albumin showed no effect on AKI or need for RRT in severe sepsis [74] but enabled a less positive fluid balance, confirming the results of another small trial [75]. A post hoc analysis of the ALBIOS trial showed survival benefit in septic shock [74] confirmed by meta-analyses [76, 77]. Hypoalbuminaemia in cardiac surgery might be another indication with improved fluid balance as well as a reduced rate of AKI being observed in a single-centre RCT of 220 patients [78].

Hypovolaemia may also contribute significantly towards drug-induced renal injury, although the available evidence supporting preventative hydration is only observational with no consensus related to timing, optimal volume and type of solution [19, 79, 80]. Prophylactic volume expansion has been shown to prevent harm from amphotericin B, antivirals including foscarnet, cidofovir and adefovir [81–83] as well as drugs causing crystal nephropathy such as indinavir, acyclovir, and sulfadiazine [84].

Prophylactic volume expansion is the mainstay of all recommendations to prevent contrast-associated AKI (CA-AKI) and is based on several randomised controlled studies performed in non-critically ill patients [85–90]. However, studies comparing hydration to no hydration are scarce [91]. Several pitfalls should be considered. First, CA-AKI is a diagnosis of exclusion and considerable variation exists with regard to the reported incidence rates, which are confounded by many factors such as transient fluctuations in measured serum creatinine in hospitalised patients and use of non-standardised diagnostic criteria [92]. Secondly, CA-AKI does not occur in patients without other risk factors for AKI, whereas most critically ill patients receiving intravascular contrast have other risk factors. Moreover, individuals with high risk for CA-AKI may not be given contrast. For these reasons the role of CA-AKI is uncertain, particularly in an era where the use of low- or iso-osmotic agents and lower contrast volume administration have become standard practice. As indicated by an analysis of the Nationwide Inpatient Sample dataset comprising 5,931,523 hospitalisations the OR for CA-AKI adjusted for age, sex, mechanical ventilation and combined co-morbidity score was 0.93 (0.88–0.97) [93]. Whereas a retrospective single-centre cohort study in 747 critically ill patients showed a rate of CA-AKI of 16% [94], matched cohort studies could not demonstrate a relationship with IV contrast for computed tomography in the ICU [95–97] or emergency department [98]. These findings are supported by a systematic review and Bayesian meta-analysis [99]. In the most recent propensity-matched cohort study, IV contrast was not associated with an increased risk of AKI or dialysis, but a subgroup with pre-CT eGFR of at most 45 ml/min/1.73 m² showed an increased risk of dialysis. The numbers in this subgroup were, however, small and subject to selection bias [97].

Although it seems prudent to correct hypovolaemia before contrast administration, prophylactic volume expansion in critically ill patients who are euvoalaemic cannot be recommended on the basis of current data. No study demonstrates protection of pre-emptive volume expansion against CA-AKI in the critically ill. An RCT comparing hydration with isotonic bicarbonate versus normal saline failed to show superiority of either regimen but reported an excessively high rate of CA-AKI of 33% in both groups [100], which may be attributed to severity of illness in this critically ill cohort. Importantly, in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI), hydration volumes above 11 ml/kg body weight (BW) were associated with continuously increased rates of AKI, requirement for RRT and mortality. The adjusted OR for developing AKI with hydration volumes greater than 25 ml/kg BW was 2.11 (CI 1.24–3.59) [101]. We recommend that the clinical decision to perform a contrast study in ICU patients must weigh the potential benefits with the low but probably not zero risk of CA-AKI.

**Diuretics**

**Recommendations**

1. **We recommend** against loop diuretics given solely for the prevention of acute kidney injury (Grade 1B).
2. **We suggest** using diuretics to control or avoid fluid overload in patients that are diuretic-responsive (Grade 2D).

**Rationale**

Oligoanuria is frequently the first indicator of acute renal dysfunction. Intensivists frequently use loop diuretics in
a wide spectrum of AKI settings [102]. The rationale for using diuretics to ameliorate AKI includes prevention of tubular obstruction, reduction in medullary oxygen consumption and increase in renal blood flow as well as reducing fluid overload and venous congestion [103–105]. Although there is no single parameter for fluid overload, increased CVP [106], peripheral oedema [107] and/or increased intra-abdominal pressure [108, 109] may be used as surrogates. A recent study demonstrated that a urinary output of at least 100 ml/h following a test dose of 1.0–1.5 mg furosemide/kg BW predicted reduced progression to a higher stage of AKI in oliguric patients [110].

Clinical studies
Use of conservative fluid management including diuretics has been investigated in only one large RCT in patients with acute lung injury (FACTT trial) which showed a tendency to reduced requirement of RRT [111]. In cardiac surgery either no protection [112] or elevated postoperative serum creatinine levels were found in patients receiving furosemide [113]. These findings were supported by a recent meta-analysis [114]. In patients with acute heart failure, diuretic therapy with higher doses was more effective at reducing clinical symptoms, but at the cost of decreased renal function [115]. To date four RCTs have examined the role of diuretics in established renal failure in the intensive care setting. No demonstrable improvements in clinically relevant outcomes, such as recovery of renal function or mortality, were observed [31, 116–118]. Other studies compared diuretics with dopamine or placebo, again with no perceived benefit [119–121]. Three meta-analyses confirmed that the use of diuretics in established AKI did not alter outcome but carried a significant risk of side effects such as hearing loss [122–124] (ESM_2 Table S5).

Vasopressors
Recommendations
1. We recommend titrating vasopressors to a mean arterial pressure (MAP) of 65–70 mmHg (Grade 1B) rather than a higher MAP target (80–85 mmHg) in patients with septic shock. However, for patients with chronic hypertension we recommend aiming for a higher target (80–85 mmHg) for renal protection in septic shock (Grade 1C).
2. We recommend lowering systolic pressure to 140–190 mmHg rather than to 110–139 mmHg in patients with acute cerebral haemorrhage with severe admission hypertension (Grade 1C).
3. If vasopressors are needed for treatment of hypotension, we recommend norepinephrine (along with correction of hypovolaemia) as the first-choice vasopres-

Rationale for MAP target
Preservation or improvement of renal perfusion can theoretically be achieved through increasing cardiac output by fluid resuscitation or inotropic drugs, through renal vasodilators or systemic vasopressors. Optimal target mean arterial pressure (MAP) was studied in a large open-label multicentre RCT randomising 777 patients with septic shock to resuscitation with a MAP target of either 80–85 mmHg or 65–70 mmHg [125]. In most of the patients the achieved MAP was above the set target. The study found no difference in mortality, incidence of AKI stage 2 (38.7% vs. 41.5%, p = 0.42) or need for RRT (33.5% vs. 35.8%, p = 0.5), but more atrial fibrillation in the high target group. However, in patients with known chronic hypertension a higher MAP resulted in a lower incidence of AKI stage 1 (38.9% vs. 52%, p = 0.02) and less RRT (31.7% vs 42.2%, p = 0.046); mortality was unchanged.

The safety of lowering systolic pressure was studied in a larger RCT in patients with acute cerebral haemorrhage with severe hypertension on admission [126]. Patients were randomised to a systolic blood pressure target of 110–139 or 140–179 mmHg. The primary endpoint (death or disability) was not different between groups. However, the rate of serious renal adverse events was higher in the lower target group (9% vs. 4%, p = 0.002) (ESM_2 Table S5).

Rationale for choice of vasopressor
Norepinephrine is the most commonly used vasopressor in patients with vasodilatory shock. A large RCT comparing dopamine to norepinephrine as initial vasopressor in patients with shock found no difference in mortality between randomised groups. However, norepinephrine was associated with less tachycardia in the first hours and was superior regarding survival in cardiogenic shock patients. In addition, there was a trend towards more RRT-free days through day 28 in the norepinephrine group [127].

Vasopressin or the analogue terlipressin may have a role in the treatment of norepinephrine-refractory shock [128]. Exogenous vasopressin has vasoconstrictive and antidiuretic properties and may increase glomerular filtration by preferential post-glomerular vasoconstriction [129]. In the largest RCT in septic shock (VASST trial), vasopressin reduced mortality in the subgroup with less severe shock, but not in the entire population. There were
and correction of hypovolaemia is therefore crucial. Hypotension may further compromise renal perfusion 
by vasoconstriction, thus unmasking occult hypovolaemia.vasoconstriction, thus unmasking occult hypovolaemia. 

Several issues should be considered. First, vasodilators 
[138]. When using vasodilators for kidney protection, 
perfusion problem during sepsis seems to occur at the 
early stage of ischaemic AKI, renal blood flow 
(RBF) falls because of stimulation of the sympathetic 
nerve and the release of vasoconstrictors such as 
endothelin, angiotensin II and vasoconstrictive prostanoids [134, 135]. In contrast, during septic AKI global 
RBF seems to be well preserved [136, 137]. The main 
perfusion problem during sepsis seems to occur at the 
microvascular level and regionally in the outer medulla 
[138]. When using vasodilators for kidney protection, 
several issues should be considered. First, vasodilators 
may cause hypotension by counteracting compensatory 
vasoconstriction, thus unmasking occult hypovolaemia. 
Hypotension may further compromise renal perfusion 
and correction of hypovolaemia is therefore crucial. 
Second, as a result of endothelial damage, nitric oxide (NO)- 
dependent vasodilators seem to be ineffective [135]. 

Third, timing may be crucial, since delayed administra-
tion reduces effectiveness as a result of occlusion of the 
microcirculation [139].

Clinical studies

Low-dose or ‘renal’ dose dopamine has been advocated 
in the past to prevent selective renal vasoconstriction 
in a variety of conditions. This may not be the case in com-
plicated clinical conditions, where low-dose dopamine may 
even worsen renal perfusion [140]. Several meta-analyses 
have concluded that ‘renal-dose’ dopamine has no benefit 
in either preventing or ameliorating AKI in the critically 
ill [141–143], the latest [141] being presented in ESM_2 
Table S6.

Fenoldopam is a pure dopamine-A1 receptor agonist 
providing systemic and renal vasodilation and natriuresis, 
and it has been studied in cardiovascular surgery and 
critically ill patients. Two older meta-analyses, one 
including 1290 critically ill and surgical patients (mainly 
cardiovascular) from 16 RCTs and the other including 
1059 cardiac surgery patients from 13 (partially overlap-
ning) RCTs and case-matched studies, reported that the 
use of fenoldopam reduced the incidence of AKI, need 
for RRT and hospital mortality [144]. Most studies were 
small with a moderate to high risk of bias and in the 
second meta-analysis 30% of the included studies were 
abstracts. The two most recent meta-analyses in cardiac 
surgery and major surgery used stricter inclusion criteria 
[145, 146] and only found a lower risk for AKI, but not 
for RRT or death. In addition, both showed an increased 
risk of hypotension and most included studies had a high 
risk of bias due to low sample size and fragility index, 
and use of different definitions for AKI. The most recent and 
largest RCT in post cardiac surgery patients with AKIN 
stage I [147] did not show any renal protection or clinical 
benefit from the use of fenoldopam, while fenoldopam 
conferred more hypotension. (Studies are summarized in 
ESM_2 Table S7).

Atrial natriuretic peptide (ANP) is produced by car-
diac atria in response to an acute increase in stretch and/
or pressure and induces afferent dilatation and efferent 
vasoconstriction, thereby increasing glomerular filtration 
and urinary sodium excretion with a dose-dependent 
hypotensive effect [148, 149]. B-type (brain) natriuretic 
peptide (BNP) is primarily produced in the cardiac 
ventricles and has similar effects [150, 151].

The two most recent meta-analyses including RCTs in 
the cardiac and cardiovascular surgery population found 
that the prophylactic infusion of low-dose ANP reduced 
postoperative peak creatinine [152] and the need for RRT 
[152–154]. However, the latter was based on only 24 cases 
of RRT in 563 patients. No effect was found in estab-
lished AKI and high-dose ANP was associated with more
frequent adverse effects (arrhythmias, hypotension) [154]. Two later RCTs on the use of ANP in aortic arch (n = 42) and high-risk cardiac surgery (n = 367) confirmed a reduction in postoperative AKI and need for RRT (0/183 vs. 7/184, p = 0.015) [155, 156] (ESM_2 Table S8).

A recent meta-analysis including 15 RCTs in 9623 patients with acute decompensated heart failure showed that the use of BNP (nesiritide) was associated with worsening renal function: RR 1.08 (1.01–1.15), especially in the subgroup receiving a high dose (>0.01 μg/kg/min) and in patients without CKD [157].

In general, most BNP trials were small, not powered for the endpoints RRT or mortality, of poor quality with low fragility index; inclusion criteria varied and results were heterogeneous. Furthermore, hypotension and arrhythmia were frequently reported. A small subgroup meta-analysis on BNP in cardiovascular surgery also showed no benefit [152] (ESM_2 Table S8).

The calcium sensitizer levosimendan has inodilator, cardioprotective and anti-inflammatory effects [158, 159]. In a recent meta-analysis of RCTs in the cardiac surgery population (13 trials, 1345 patients), the use of levosimendan decreased the risk of AKI [OR 0.51 (0.24–0.79)], the need for RRT [OR 0.43 (0.25–0.76)] and mortality [OR 0.41 (0.27–0.62)] [160]. The last meta-analysis of RCTs in the critically ill population with or at risk of AKI (33 RCTs, 3867 patients) found that, compared to placebo or another inotrope, levosimendan decreased the risk of AKI [RR 0.79 (0.63–0.99)] and the need for RRT [RR 0.52 (0.32–0.86)]. When limiting the analysis to high-quality studies, the difference in need for RRT between groups failed to reach significance [RR 0.41 (0.15–1.12)] [161]. Studies in both meta-analyses were small, there was some heterogeneity, AKI was not always a predefined endpoint, different definitions of AKI were used and there might have been some outcome reporting bias.

Three large placebo-controlled RCTs have recently been published. In patients with sepsis the use of levosimendan was not beneficial in terms of a reduction of renal SOFA, need for RRT [OR 0.99 (0.66–1.49)] or mortality [OR 1.19 (0.82–1.72)], while its use was associated with more adverse events [162]. In 882 patients with left ventricular dysfunction undergoing cardiac surgery, levosimendan had no effect on mortality or need for RRT [163]. No effect on AKI and RRT was seen when levosimendan was given for haemodynamic support after cardiac surgery in 506 patients [164] (ESM_2 Table S9).

Sedation

Recommendations

1. On the basis of current data no recommendation can be given, although it appears that shorter sedation using propofol or dexmedetomidine may have several advantages, possibly reducing the rate of AKI (BPS).

Rationale

Sedation is necessary in many critically ill patients and this may affect cardiac function and/or vascular tone with renal consequences. In animal models propofol reduced markers of oxidative stress in the kidney [165, 166] and dexmedetomidine caused diuresis through reducing vasopressin secretion, enhancing renal blood flow and hence glomerular filtration [167] and showed renal protection [168–171].

Clinical studies

Propofol is commonly used as anaesthetic and for sedation in the intensive care unit [172]. The “propofol infusion syndrome” comprises myopathy, rhabdomyolysis, hyperkalaemia and AKI [173, 174]. On the basis of the data from case reports/series, it is recommended to administer propofol for a maximum of 48 h and a maximum dose of 4 mg/kg/h [175]. On the other hand, a recent propensity-matched cohort study in critically ill patients showed reduced risk of AKI and need for RRT in patients sedated with propofol as compared to midazolam [176]. Furthermore a small RCT including 112 patients undergoing valvular heart surgery showed less AKI and significantly lower cystatin C levels in the group treated with propofol as compared to sevoflurane [177]. However, the fact that remote ischaemic preconditioning showed less effect if patients were treated with propofol leaves uncertainty about the protective effect of propofol on the kidney [178].

α-2 Adrenergic agonists have multiple pharmacodynamic effects [179]. In a placebo-controlled double-blind RCT dexmedetomidine demonstrated significant diuretic effects, with an almost 75% increase in diuresis after cardiac surgery, but did not affect renal function per se [180]. Observational trials indicated protection of kidney function after cardiac surgery [181] but not when used for sedation during lung cancer resection [182]. A placebo-controlled study in 90 patients undergoing coronary artery bypass graft (CABG) showed a dose-dependent reduction of NGAL levels with dexmedetomidine used for postoperative sedation [183]. Another RCT in 200 patients showed that dexmedetomidine for 24 h at 0.4 μg/kg/h from start of anaesthesia resulted in reduced rate of AKI, morbidity and length of stay in the ICU [184] (ESM_2 Table S10).

Alltogether, the data for non-benzodiazepine sedatives, especially dexmedetomidine, are promising but currently not sufficiently convincing to give a clear recommendation.
Hormonal manipulation

Recommendations

1. We **suggest** targeting a blood glucose level at least below 180 mg/dL (10 mmol/l) for the prevention of hyperglycaemic kidney damage in the general ICU population (Grade 2B).

2. We **suggest** not using erythropoietin (Grade 2B) or steroids (Grade 2B) for prevention of acute kidney injury.

Rationale

In critical illness hyperglycaemia has been associated with adverse outcomes [185, 186] attributed to oxidative stress, endothelial dysfunction, alterations in haemostasis, immune dysregulation and mitochondrial dysfunction. The anti-inflammatory effect of steroids may attenuate the inflammatory component of AKI pathogenesis. Erythropoietin (EPO), besides being a haematopoietic growth factor, also has tissue-protective properties by decreasing apoptosis and inflammation and by promoting neovascularization and tissue regeneration.

Clinical studies

A large prospective RCT in 1548 surgical ICU patients compared **tight glucose control (TGC)** with insulin (target blood glucose 80–110 mg/dL) to standard care (insulin when blood glucose is greater than 200 mg/dL resulting in a mean blood glucose of 150–160 mg/dL) and showed not only an improved survival rate but also a 41% reduction in AKI requiring RRT [187]. Additionally, TGC also reduced the number of patients with peak plasma creatinine greater than 2.5 mg/dL by 27%. A subsequent study in the medical ICU of the same hospital, including many patients that already had AKI on admission, did not confirm the effect on survival or need for RRT, but showed a 34% reduction in AKI, defined as a doubling of serum creatinine compared with the admission level [188]. A combined analysis of both studies showed a more pronounced renal protection when normoglycaemia was achieved [189].

More recent RCTs in septic [65] and general [190–194] ICU patients (some of which had to be stopped early because of hypoglycaemia) including a large adequately powered multicentre trial in Australia and New Zealand (NICE-SUGAR) [191] did not confirm the renoprotective effect. The latter even found a higher mortality in patients treated with TGC compared to an intermediate level. Clinicians should, however, be aware of important differences between these landmark trials, such as the glycaemic target in the control group, the nutritional strategy and the methods used to measure blood glucose levels [195]. The most recent meta-analysis on this issue did not find a mortality benefit [RR 1.06 (0.99–1.13)] [196] of TGC nor a renoprotective effect (evaluated by the need for RRT only) [RR 0.96 (0.83–1.11)] [196] (ESM_2 Table S11).

A major obstacle to the broad implementation of TGC is the increased risk of hypoglycaemia. Patients with AKI are at particular risk [197]. On the other hand, a causal relationship between a short-lasting iatrogenic hyperglycaemia in the monitored setting of an ICU and outcome remains controversial [198–200]. If clinicians decide to adopt TGC strategies, fluctuations in glucose levels should be minimized and reliable tools should be employed to measure blood glucose [195]. Because of the risk of hypoglycaemia, current guidelines suggest more moderate blood glucose targets (less than 180 mg/dL [20], less than 150 mg/dl [52], 140–180 mg/dL [201]) in critically ill patients, although these targets have not been formally compared with tolerating hyperglycaemia [202] (ESM_2 Table S11).

A recent large RCT (n = 4494) demonstrated no significant effect of the intraoperative administration of **dexamethasone** on a composite endpoint of major complications after cardiac surgery. The RR for RIFLE-Failure was 0.7 (0.44–1.14) [203]. A post hoc analysis of this trial showed a beneficial effect on the need for RRT (RR 0.44 (0.19–0.96)), an effect that was mainly seen in patients with eGFR less than 15 ml/min/1.73 m² and remains to be confirmed [204]. Another placebo-controlled RCT in 7507 patients found no effect of methylprednisolone on the incidence of AKI stage 3 after cardiac surgery [205].

Prospective randomised placebo-controlled trials on the renoprotective effect of **erythropoietin** have mainly been performed in the setting of cardiac surgery [206–210]. A recent meta-analysis (5 studies, 423 patients) found no effect of erythropoietin on the incidence of AKI: RR 0.64 (0.35–1.16). Surprisingly, a preplanned subgroup analysis found a significant reduction of AKI in patients without high risk for AKI: RR 0.37 (0.24–0.61; p < 0.0001) [211]. Similar results were obtained in the most recent meta-analysis, which in addition showed more protection with pre-anaesthetic administration [212]. Another RCT in cardiac surgery including 75 patients with pre-existing renal impairment found no differences in postoperative levels of serum creatinine, cystatin C or NGAL [213]. A second meta-analysis (on a total of 2759 patients) that also included studies in ICU patients [214, 215] likewise did not establish a renoprotective effect of erythropoietin: incidence of AKI RR 0.72 (0.79–1.19); dialysis requirement RR 0.72 (0.31–1.70), mortality RR 0.96 (0.78–1.18), all without significant heterogeneity amongst studies [216]. It should, however, be emphasized that in the largest study in ICU patients [215] AKI was only reported as an adverse effect and not clearly defined. Two more recent RCTs in the setting of
thoracic aortic surgery [217] and contrast administration in diabetics [218] confirmed the absence of beneficial effect of EPO on the incidence of AKI or need for RRT in critically ill patients (ESM_2 Table S12).

**Metabolic interventions**

**Recommendations**

1. We recommend not using high-dose IV selenium for renal protection in critically ill patients (1B).
2. We suggest not using N-acetylcysteine to prevent contrast-associated AKI in critically ill patients because of conflicting results and possible adverse effects (Grade 2B).
3. We suggest that all patients with or at risk of acute kidney injury have adequate nutritional support preferably through the enteral route (BPS).

**Rationale**

Starvation accelerates protein breakdown and impairs protein synthesis in the kidney, whereas feeding might exert the opposite effects and promote renal regeneration. In animal experiments increased protein intake has been shown to reduce tubular injury [219, 220], and enteral versus parenteral nutrition improved the resolution of AKI [221]. On the other hand, amino acids infused before or during ischaemia may also enhance tubular damage and accelerate loss of renal function [222]. This may also extend to high-dose glutamine when given to patients during the injury phase of AKI [223]. Furthermore, brief periods of reduced food intake appear to increase resistance against ischaemia–reperfusion injury in rodents [224]. This “amino acid paradox” may be related to the increase in metabolic work for transport processes which may aggravate ischaemic injury. Enhanced autophagy, induced by nutrient deprivation and promoting the repair of cellular damage, may be an alternative explanation. In this context permissive underfeeding during the acute phase of critical illness may be protective against AKI.

One aspect of nutrition is the adequate supply of nutritional co-factors and antioxidants such as the glutathione precursor N-acetylcysteine (NAC), antioxidant vitamins (vitamin E (α-tocopherol) and vitamin C (ascorbic acid)) as well as selenium. However, these antioxidants have also been investigated in pharmacological doses with the intention to provide protection against damage by oxygen radicals.

**Clinical studies**

Protein(s) and amino acids augment renal perfusion and improve renal function, representing recruitment of “renal reserve capacity” [225]. An RCT investigating the effects of daily intravenous amino acid supplementation up to 100 g/day in 424 critically ill patients could not find a significant effect on the duration of AKI despite an increase in eGFR in the treatment group [226]. Furthermore, there was a trend towards increased need for RRT which corresponds to findings from the EPaNIC trial where early parenteral nutrition increased the duration of RRT probably driven by higher urea levels [227]. Correspondingly, lower caloric intake (defined as receiving less than 60% of requirements, also called permissive underfeeding) has been found to be associated with a lower risk for RRT (RR 0.711, 95% CI 0.545–0.928) [228].

A host of RCTs have been performed comparing NAC to placebo or other interventions with or without hydration in non-critically ill patients receiving radiocontrast media [229–237]. Results are controversial as alluded to earlier but the latest meta-analysis assessing the efficacy of intravenous NAC only showed no reduction of AKI or RRT [238]. The ACT trial, currently the largest RCT including 2308 patients undergoing coronary and peripheral vascular angiography, failed to demonstrate any beneficial effect of NAC [239]. RCTs in the critically ill population are not available.

RCTs examining the role of NAC in the prevention of renal dysfunction in high-risk contexts like cardiac surgery showed controversial results [240–246] (ESM_2 Table S13). In addition IV NAC may be harmful leading to allergic reactions [247] and decreased cardiac output or survival in patients with septic shock [248, 249].

A small RCT in 42 patients showed that selenium supplementation decreased the requirement for RRT from 43% to 14% in patients with SIRS [250]. These finding could, however, not be reproduced in consecutive trials [251] including two larger RCTs involving 249 and 1089 patients with sepsis [252, 253].

**Statins**

**Recommendations**

1. We recommend against the perioperative use of high-dose statins to prevent postoperative AKI in cardiac surgery (Grade 1A).
2. We suggest the short-term use of atorvastatin or rosuvastatin to prevent contrast-associated AKI in high-risk patients undergoing coronary contrast angiography (Grade 2B).

**Rationale**

The pleiotropic effect of statins, including antioxidant, anti-inflammatory and antithrombotic effects, may contribute to nephroprotection [254].
Clinical studies

Statins may have a beneficial role in high-risk patients exposed to contrast administration for angiography, as suggested by three recent RCTs [255–257]. In a multicentre trial in China, 2998 patients with type 2 diabetes or mild to moderate CKD undergoing coronary or peripheral arterial angiography were randomised to a 5-day course of rosuvastatin versus no statin [255]. The incidence of CA-AKI was significantly lower in those receiving rosuvastatin (2.3% vs. 3.9%, respectively, p = 0.01). In a single-centre study [256], 504 statin-naïve patients with acute coronary syndrome (ACS) scheduled to undergo an early invasive strategy were randomised to high-dose rosuvastatin at the time of admission versus treatment with atorvastatin commenced at hospital discharge; 6.7% of patients in the early high-dose statin group developed CA-AKI compared to 15.1% in the control group. The 30-day rate of adverse cardiovascular and renal events was also significantly reduced in the rosuvastatin group (3.6% vs. 7.9%, respectively, p = 0.036).

An RCT in 410 CKD patients showed less CA-AKI in patients randomised to a single dose of atorvastatin within 24 h before contrast exposure compared to the control group (4.5% vs. 17.8%, p = 0.005) [257]. Two more recent RCTs found similar effects of statins in diabetics with CKD [258, 259]. These positive findings were confirmed by several meta-analyses combining studies in patients undergoing coronary angiography [260–263] (ESM_2 Table S14). One of these meta-analyses concluded that short-term, pre-procedural, intensive statin treatment only reduced CA-AKI in ACS patients and recommended further studies in non-ACS patients [264]. This meta-analysis, however, did not include the largest RCT [255]. Although, these results lend support to the short-term use of statins before procedures involving intra-arterial contrast exposure in patients with coronary artery disease with or without diabetes and/or CKD, it must be considered that most of the studies were performed outside the ICU, thereby warranting downgrading of the level of evidence.

In patients undergoing cardiac surgery, two large meta-analyses including data from observational studies found conflicting evidence regarding the role of preoperative statin in preventing postoperative AKI [265, 266], and a Cochrane analysis of small RCTs found no effect [267]. Two recent placebo-controlled RCTs investigated the effects of perioperative high-dose atorvastatin (i.e. 80 mg, followed by 40 mg daily) in elective cardiac surgery [268] and valvular heart surgery [269] and showed no renal benefit. Furthermore, in the largest trial, statin-naïve patients with CKD had a higher incidence of AKI when treated with statin [268] (ESM_2 Table S15). Finally, an even larger placebo-controlled RCT in 1922 cardiac surgery patients that included AKI as a secondary outcome demonstrated renal harm in those receiving rosvastatin 20 mg/day in the perioperative period [270].

Remote ischaemic preconditioning

Recommendations

1. We suggest not using remote ischaemic preconditioning for prevention of AKI in critically ill patients (Grade 2A).

Rationale

Remote ischaemic preconditioning (RIPC) or several short cycles of limb ischaemia is achieved through inflation of a blood pressure cuff. The mechanism by which RIPC prevents AKI is incompletely understood.

Clinical studies

In cardiac surgery several single-centre RCTs demonstrated reduced incidence of AKI and need for RRT [271–273]. However, several others, including four larger and multicentric RCTs [274–277] did not confirm these beneficial effects, nor was a change in creatinine or mortality demonstrated. The conflicting results in cardiac surgery may be explained by inclusion of low-risk patients in trials that showed no benefit, and the use of propofol and opioids, treatments that may blunt the beneficial effects of RIPC.

In 13 recent meta-analyses the effect of RIPC was evaluated in different cohorts and definitions of AKI [178, 278–289]. Though several meta-analyses found a reduction of AKI [278, 279, 281–284, 286, 287, 289, 290] this was restricted to stage 1 AKI [289], or subgroups such as percutaneous coronary interventions [278, 279], or cardiac surgery with propofol-free anaesthesia [283]. The meta-analyses are limited by risk of bias, heterogeneity in definitions of AKI, low event rates and underestimation of influence of co-morbidities [283, 289]. Finally, a Cochrane review including studies on patients undergoing surgery could not show a benefit on renal outcomes [178] (ESM_2 Table S16).

In summary, the effects by which RIPC prevents AKI are incompletely understood. RIPC for prevention of AKI has mainly been evaluated in cardiovascular surgery and after contrast administration. Larger studies and meta-analyses are not consistent in demonstrating a preventive effect of RIPC for AKI.
**AKI care bundles**

**Recommendations**

1. We suggest using the KDIGO recommendations to reduce the incidence of AKI after cardiac surgery (Grade 2C).
2. The use of AKI care bundles outside the intensive care unit has some benefits, including the potential to improve the outcome of AKI (BPS).

**Rationale**

Care bundles have been proposed as tools to improve the quality of care and outcome of patients with AKI. Ideally, they should contain a small set of practices, processes or treatments that are evidence-based, endorsed and/or recommended by guidelines and broadly accepted as appropriate and/or standard care by local stakeholders. They are designed such that if one element is not implemented, the remaining elements are not impacted.

**Clinical studies**

Outside the critical care setting, different AKI care bundles have been implemented with variable improvement in clinical care, more efficient resource use and potentially improved outcomes, especially if combined with educational measures and electronic alerting [291–293]. To date, care bundles comprising the KDIGO recommendations have only been investigated in one study including 274 cardiac surgery patients at high risk for AKI as determined by AKI biomarkers. The study showed less postoperative AKI (although mainly by the urine output criteria) without, however, influencing any major patient-centred outcome like RRT or renal recovery at day 30 [294]. The treatment strategy included avoidance of nephrotoxins and hyperglycaemia as well as applying goal-directed haemodynamic optimisation. It is unclear which element was effective because goal-directed therapy (GDT) neither prevented AKI nor reduced the need for RRT in septic shock, as shown by a secondary analysis [23] and a meta-analysis of three recent large RCTs [295], but avoiding nephrotoxins, hyperglycaemia and hypovolaemia seems to be reasonable.

**Conclusions and summary**

Prompt resuscitation of the circulation with fluids, vasopressors and inotropes remains the cornerstone in the prevention of AKI. Volume expansion with isotonic crystalloids is only recommended in states of true and suspected hypovolaemia. Uncontrolled volume expansion and the use of starches and dextrans should be avoided. Following or together with fluid resuscitation hypotensive patients should be given a vasoconstrictor, preferably norepinephrine, and titrated individually with a target MAP of 65–70 mmHg being adequate in most individuals without pre-existing chronic hypertension. The potential role of vasopressin requires further investigation. Together with these measures a review of all medications with the cessation of those known to be nephrotoxic is mandatory. Diuretics should not be used for prevention of AKI alone but may benefit the kidney by relieving renal congestion. Frank hyperglycaemia should be avoided. The effect of statins appears to depend on the setting, with promising results in contrast administration but no effect or even harm in cardiac surgery. There is low-level evidence that the choice of the sedative may impact kidney function. The conflicting results on ischaemic preconditioning preclude a firm recommendation.

Heterogeneous definitions of AKI still hamper comparison of different studies, despite the commendable efforts by the ADQI, AKIN and KDIGO working groups [2, 296, 297]. In addition, AKI is frequently reported as a secondary outcome. Although several RCTs have fuelled the literature on prevention of AKI over the past 4–5 years, the available evidence remains insufficient. Many recommendations are therefore formulated as weak with low grade quality of evidence. More high-quality studies with consensus AKI definitions will be required to fill the knowledge gaps.

**Electronic supplementary material**

The online version of this article (doi:10.1007/s00134-017-4832-y) contains supplementary material, which is available to authorized users.

**Acknowledgements**

Open access funding provided by University of Innsbruck and Medical University of Innsbruck.

**Author details**

1 Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstasse 35, 6020 Innsbruck, Austria. 2 Department of Internal Medicine III, University Hospital Vienna, Vienna, Austria. 3 Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey and Surrey Perioperative Anaesthesia and Critical Care Collaborative Research Group (SPACeR), Intensive Care Unit, Royal Surrey County Hospital NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, United Kingdom. 4 Department of Intensive Care, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium. 5 Department of Intensive Care Medicine, Ghent University Hospital, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium. 6 Department of Critical Care and Nephrology, Guy’s and St Thomas’ Hospital, London, United Kingdom. 7 Department of Adult Intensive Care, VU University Medical Centre, De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands. 8 Clinical Department and Laboratory of Intensive Care Medicine, Division of Cellular and Molecular Medicine, KU Leuven University, Leuven, Belgium.

**Compliance with ethical standards**

**Conflicts of interest**

MJ has received honoraria or research support from Baxter Healthcare Corp, AM-Pharma, CLSBehring, Fresenius and Astute Medical. WD declares no conflicts of interest. LF has received honoraria and research support from Astute Medical, Fresenius, Baxter Gambro Renal and Orthoclinical Diagnostics. PH has received research grants from Baxter, AM Pharma, Belico, and Pfeifer & Langen. MD received speaker’s fees from Alexion and Astute Medical, and a research grant from Belico. MO has received honoraria and research funding from Fresenius Medical Care and Baxter Gambro. HO has financial congress support from Drinco (Netherlands) and speaker’s honoraria from Fresenius and Gambro/Baxter. MS declares no conflicts of interest.
Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Received: 10 April 2017  Accepted: 2 May 2017
Published online: 2 June 2017

References

1. Chertow GM, Burdick E, Honour M (2005) Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16:3365–3370

2. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:1–138

3. Kanne-Gill SL, Sileanu FE, Murugan R, Trietley GS, Handler SM, Kellum JA (2015) Risk factors for acute kidney injury in older adults with critical illness: a retrospective cohort study. Am J Kid Dis 65:860–869

4. Kirwan CJ, Blunden MJ, Dobbie H, James A, Nedungadi A, Prowle JR (2015) Critically ill patients requiring acute renal replacement therapy are at an increased risk of long-term renal dysfunction, but rarely receive specialist nephrology follow-up. Nephron 129:164–170

5. Joannidis M, Metnitz B, Bauer P, Schusterschitz N, Moreno R, Druml W, Metnitz PG (2009) Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. Intensive Care Med 35:1692–1702

6. Hoste EA, Bagshaw SM, Belloso R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honore PM, Joannes-Boyau O, Juillard L, Journois D, Lautrette A, Muller L, Legrand M, Takala J, Sprung C, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP (2017) Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377

7. Piccinni P, Cruz DN, Gramaticopolo S, Garzotto F, Dal Santo M, Aneloni C, Brienza N, Carlini M, Pelaia P, Gabbanelli V, Ronco C, Investigators N (2011) Prospective multicenter study on epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 37:1411–1423

8. Bell S, Dekker FW, Vadevelo T, Marwick C, Deshmukh H, Donnan PT, Van Diepen M (2015) Risk of postoperative acute kidney injury in patients undergoing orthopaedic surgery—development and validation of a risk score and effect of acute kidney injury on survival observational cohort study. BMJ 351:h5639

9. Joannidis M, Druml W, Forni LG, Groeneveeld AB, Honour M, Oudemans-van Straaten HM, Ronco C, Schetz MR, Wootz AJ, Critical Care Nephrology Working Group of the European Society of Intensive Care Medicine (2010) Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM. Intensive Care Med 36:392–411

10. Ichai C, Vinsonneau C, Souweine B, Armando F, Canet E, Clech C, Constantin JM, Darmon M, Duranteau J, Gaillot T, Garner A, Jacob L, Joannes-Boyau O, Juillard L, Journouis D, Lautrette A, Muller L, Legrand M, Lerrole N, Rimelle T, Rondeau E, Tamion F, Wiltart Y, Welly L, Société française d’anesthésie et de réanimation (Sfar), Société de réanimation de langue française (SRLF), Groupe francophone de réanimation et urgences pédiatriques (GFRUP), Société française de néphrologie (SFN) (2016) Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies). Ann Intensive Care 6:48

11. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schumemann HU (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924–926

12. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter Y, Schumemann HU (2011) GRADE guidelines. 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64:395–400

13. Guyatt GH, Schumemann HU, Djulbegovic B, Akl EA (2015) Guideline panels should not GRADE good practice statements. J Clin Epidemiol 68:597–600

14. de Mendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M, Takala J, Sprung C, Caenardeau F (2000) Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 26:915–921

15. Guerin C, Girard R, Selli JM, Perdrix JP, Ayazac L (2000) Initial versus delayed acute renal failure in the intensive care unit. A multicenter prospective epidemiological study. Rhone-Alpes Area Study Group on Acute Renal Failure. Am J Respir Crit Care Med 161:872–879

16. Schwilk W, Wiedeck H, Stein B, Reineit H, Treiber H, Bothner U (1997) Epidemiology of acute renal failure and outcome of haemodiafiltration in intensive care. Intensive Care Med 23:1204–1211

17. Himmelfarb J, Joannidis M, Moltotris B, Schietz M, Okusa MD, Warnock D, Laghi F, Goldstein SL, Prellip M, Parikh CR, Pannu N, Lobo SM, Shah S, D’Intini V, Kellum JA (2008) Evaluation and initial management of acute kidney injury. Clin J Am Soc Nephrol 3:962–967

18. Joannidis M (2004) Drug-induced renal failure in the ICU. Int J Artif Organs 27:1034–1042

19. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Uhlmann ME, Rosengart C, Rubenstein GD, Angus DC, Armane D, Beale RJ, Bellinghan GM, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fukushima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karmad NR, Kleinpohl RM, Koh Y, Libsow TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Pernier A, Plunkett OM, Raniens C, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukr MA, Simpson SG, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WI, Zimmerman J, Dellinger RP (2017) Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377

20. Prowle JR, Kirwan CJ, Bellomo R (2014) Fluid management for the prevention and attenuation of acute kidney injury. Nat Rev Nephrol 10:37–47

21. Ostermann M, Straaten HM, Forni LG (2015) Fluid overload and acute kidney injury: cause or consequence? Crit Care 19:443

22. Kellum JA, Chawla LS, Keener C, Singbartl K, Palevsky PM, Pike FL, Yealy DM, Huang DT, Angus DC, ProCESS and ProGReSS-AKI Investigators (2016) The effects of alternative resuscitation strategies on acute kidney injury in patients with septic shock. Am J Respir Crit Care Med 193:281–287

23. Chowdhury AH, Cox EF, Francis ST, Lobo DN (2012) A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and Plasma-lyte® 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg 256:18–24

24. Wilkes NJ, Wollof R, Mutch M, Mallett S, Peachey T, Stephens R, Mythen MG (2001) The effects of balanced versus saline-based hetastarch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients. Anesth Analg 93:811–816

25. Alphonsus CS, Rodseth RN (2014) The endothelial glycolalyca: a review of the vascular barrier. Anaesthesia 69:777–784

26. Chappell D, Jacob M (2014) Role of the glycolalyca in fluid management: small things matter. Best Pract Res Clin Anaesthesiol 28:227–234

27. Perner A, Prowle JR, Joannidis M, Young P, Hjortrup PB, Pettilä V (2013) Fluid management in acute kidney injury. Intensive Care Med 39:81–88

28. Cesnys CS, Rodseth RN (2014) The endothelial glycolalyca: a review of the vascular barrier. Anaesthesia 69:777–784

29. Horgan KJ, Ottaviano YL, Watson AJ (1989) Acute renal failure due to mannitol intoxication. Am J Nephrol 9:106–109

30. Rozich JD, Paul RV (1989) Acute renal failure precipitated by elevated colloid osmotic pressure. Am J Med 87:359–360
31. Legendre C, Thervet E, Page B, Percheron A, Noel LH, Kreis H (1993) Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplant. Lancet 342:248–249.

32. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Rou B, Cornat P (1996) Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 348:1620–1622.

33. Skinsnes OK (1947) Gelatin nephrosis; renal tissue changes in man resulting from the intravenous administration of gelatin. Surg Gynecol Obstet 85:563–571.

34. Beyer R, Harmening U, Rittmeier O, Zielmann S, Mieck F, Kazmaier S, Kettler D (1997) Use of modified fluid gelatin and hydroxyethyl starch for colloidal volume replacement in major orthopaedic surgery. Br J Anaesth 78:44–50.

35. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery L, Femaire L, Brochard L (2001) Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 357:915–919.

36. Mardel SN, Saunders FM, Allen H, Menezes G, Edwards CM, Olleren‑van Boeijen E, deHaan J, Huet RCG, Boonstra PW, vanOeveren W (1995) Hyperoncotic colloids and acute kidney injury: a phase II multicenter double-blind randomized controlled trial. Crit Care Med 41:1599–1607.

37. Kellum JA, Lameire N, KDIGO AKI Guideline Work Group (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17:204.

38. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, SAFE Study Investigators (2004) A comparison of albumin and saline for fluid resuscitation in intensive care. N Engl J Med 350:2247–2256.

39. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knobloch B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377.

40. Senar AD, Candelaria-Toha AM, Zamora J, Vera J, Muriel A, Del Rey JM (2016) Hyperoncotic hydration with 0.9% normal saline to prevent acute kidney injury after major elective open abdominal surgery: a randomised controlled trial. Eur J Anaesthesiol 33:436–443.

41. Hjortrup PB, Haase N, Bundgaard H, Thomsen SL, Winding R, Pettilla V, Aaen L, Lodal D, Berthenes RH, Christensen H, Madsen WB, Winkel P, Wettetv H, Perner A, CLASSIC Trial Group, Scandinavian Critical Care Trials Group (2016) Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel-group, multicentre feasibility trial. Intensive Care Med 42:1695–1705.

42. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M (2012) Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 308:1566–1572.

43. Shaw AD, Raghunathan K, Peyret FW, Munson SH, Paluszewskiw SM, Schermer CR (2014) Association between intravenous chloride load during resuscitation and in-hospital mortality among patients with SIRS. Intensive Care Med 40:1897–1905.

44. Kellum JA, Lameire N, KDIGO AKI Guideline Work Group (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17:204.

45. Young P, Bailey M, Beasley R, Henderson S, Mackie D, McArthur C, McGuinness S, Mehrtens J, Myburgh J, Peirides A, Reddy S, Bellomo R (2015) Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial. JAMA 314:1701–1710.

46. Joannidis M, Forri LG (2016) Acute kidney injury: buffered colloids versus saline in the ICU—a SPLIT decision. Nat Rev Nephrol 12:6–8.

47. Semler MW, Wanderer JP, Ehrenfeld JM, Stollings JL, Self WH, Siew ED, Wang L, Byrne DW, Shaw AD, Bernard GR, Rice TW, SALT Investigators and the Pragmatic Critical Care Research Group (2017) Balanced crystalloids versus saline in the intensive care unit: the SALT randomized trial. Am J Respir Crit Care Med. doi: 10.1164/rccm.201607-1345OC.

48. Haase M, Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Reade MC, Bagshaw SM, Seevanayagam N, Seevanayagam S, Dooolan L, Buxton R, Dragun D (2009) Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. Crit Care Med 37:39–47.

49. Morino Y (1987) Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 32 (2):198–203.

50. Semler MW, Wanderer JP, Ehrenfeld JM, Stollings JL, Self WH, Siew ED, Wang L, Byrne DW, Shaw AD, Bernard GR, Rice TW, SALT Investigators and the Pragmatic Critical Care Research Group (2017) Balanced crystalloids versus saline in the intensive care unit: the SALT randomized trial. Am J Respir Crit Care Med. doi: 10.1164/rccm.201607-1345OC.

51. Kellum JA, Lameire N, KDIGO AKI Guideline Work Group (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17:204.
of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 39:558–568

Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Ferguson DA (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 309:678–688

Mutter TC, Alhazzani W, Gibson A, Ribic CM, Sinha A, Heels-Ansdell D, Thabane L, Fox-Robichaud A, Mbaubagbav L, Szczeklik W, Alshamsi F, Atyab Y, Ip W, Li G, Wang M, Wudarzyck A, Zhou Q, Annane D, Cook DJ, Jaeschke R, Guyatt GH (2015) Fluid type and the use of renal replacement therapy in sepsis: A systematic review and network meta-analysis. Intensive Care Med 41:1561–1571

Haase N, Perren A, Hennings L, Siegemund M, Lauridsen B, Wetter­sley M, Wetter­sley J (2013) Hydroxyethyl starch 130:0.38–0.45 versus crystalloid or other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 7:CD007594. doi:10.1002/14651858.CD007594.pub3.

Reinhardt K, Perren A, Sprung CL, Jaeschke R, Schortgen F, Johan Groen­eveld AB, Beale R, Hartog CS, European Society of Intensive Care Medi­cine (2012) Consensus statement of the ESMIC task force on colloid volume therapy in critically ill patients. Intensive Care Med 38:368–383

Moeller C, Fleischmann C, Thomas-Rueddell D, Vlasakov V, Rochweg B, Theurer P, Gattinoni L, Reinhardt K, Hartog CS (2016) How safe is gelatin? A systematic review and meta-analysis of gelatin-containing plasma expanders vs crystalloids and albumin. J Crit Care 35:75–83

Caironi P, Tognoni G, Masson S, Fumagalli R, Presenti A, Romero M, Fanizza C, Caspiani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Parini V, Fiore G, Latini R, Gattinoni L, ALBSO Study Investigators (2014) Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 370:1412–1421

Dubois ML, Orellana-Jimenez C, Melot C, De Backer D, Berre J, Leeman M, Brimoulle S, Appolloni O, Creteur J, Vincent JL (2006) Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. Crit Care Med 34:2536–2540

Wiedermann CJ, Joannidis M (2014) Albumin replacement in severe sepsis or septic shock. N Engl J Med 371:83

Patel A, Laffan MA, Waheed U, Brett SJ (2014) Randomised trials of human albumin for adults with sepsis: systematic review and meta­analysis with trial sequential analysis. BMJ 349:g4561

Lee EH, Kim WJ, Kim JY, Chun JH, Choi DK, Sim JY, Choo SJ, Chung CH, Lee JW, Choi IC (2016) Effect of exogenous albumin on the incidence of postoperative acute kidney injury in patients undergoing open‑pump coronary artery bypass surgery with a preoperative albumin level of less than 4.0 g/dl. Anesthesiology 124:1001–1011

Pannu N, Nadim MK (2008) An overview of drug-induced acute kidney injury. Crit Care Med 36:5216–232

Perazella MA, Luciano RL (2015) Review of select causes of drug­induced AKI. Expert Rev Clin Pharmacol 8(4):367–371

Branch RA (1988) Prevention of amphotericin-B induced renal impair­ment. A review on the use of sodium supplementation. Arch Intern Med 148:2389–2394

Cheung TW, Jayaweera DT, Pearce D, Benson P, Nahass R, Olson C, Wool MSS (2000) Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovi­rus infections. Int J STD AIDS 11:640–647

Safiri S, Cherrington J, Jaffe HS (1999) Cidofovir. Review of current and potential clinical uses. Adv Exp Med Biol 458:111–120

Perazella MA (1999) Crystal-induced acute renal failure. Am J Med 106:459–465

Solomon R, Werner C, Mann D, ELia J, Silva P (1994) Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331:1416–1420

Mueller C, Buerkle G, Buettrner HU, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskam H (2002) Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162:329–336

Merten GJ, Burgess WP, Gray JV, Hollen­man JH, Rou­sh TS, Kovach­uk GJ, Bensen RM, Van Moore A, Sim­ont­on CA 3rd, Ritt­asse RA, Norton HJ, Kennedy TP (2004) Prevention of contrast-induced nephropa­thy with sodium bicarbonate: a randomized controlled trial. JAMA 291:1238–2334

Ozcan EE, Guneri S, Akdeniz B, Akyildiz IZ, Senaslan O, Baris N, Aylan O, Badak O (2007) Sodium bicarbonate, Na-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J 154:539–544

Masuda M, Yamada T, Mine T, Morita T, Tamaki S, Tsukamoto Y, Okuda K, Iwasaki Y, Hori M, Fukunami M (2007) Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 100:781–786

Briquoir C, Arioldi F, D’Andrea D, Bonzini E, Morici N, Focaccia A, Michev I, Montor­fano M, Carlin­o M, Cos­grave J, Ricciardelli B, Colombo A (2007) Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115:1211–1217

Nijssen EC, Rennenberg RJ, Nelemans PJ, Essers BA, Janssen MM, Ver­meer­man MA, Omm­en W, Wildberger JE (2017) Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): A prospective, randomised, phase 3, controlled, open-label, non-inferior­ity trial. Lancet 389:1312–1322

Newhouse JH, Kho D, Rao QA, Starren J (2008) Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am Roent­genol 191:376–382

Wilhelm-Leen E, Mon­tez-Rath ME, Chertow G (2017) Estimating the risk of radiocontrast-associated nephropathy. J Am Soc Nephrol 28:653–659

Hoste EA, Doin­m S, De Wae­le J, Delrue LJ, Defreyne L, Benoit DD, Decruyenaere J (2011) Epidemiology of contrast-associated acute kidney injury in ICU patients: a retrospective cohort analysis. Intensive Care Med 37:1921–1931

Cely CM, Schein RM, Quartin AA (2012) Risk of contrast-induced nephropathy in the critically ill: a prospective, case matched study. Crit Care 16:967

Ehrmann S, Badin J, Savath L, Pajot O, Gordo M, Capdevila X, Per­rot­in D, Lakhal K (2013) Acute kidney injury in the critically ill: iodinated contrast medium really harmful? Crit Care Med 41:1017–1026

McDonald J, McDonald RJ, Williamson EE, Kallmes DF, KAshani K (2017) Post-contrast acute kidney injury in intensive care unit patients: a propensity score-adjusted study. Intensive Care Med. doi:10.1007/s00134-017-4699-y

Hinson JS, Ehrmann MR, Fine DM, Fishman EK, Toepfer MF, Rothman RE, Klein EY (2017) Risk of acute kidney injury after intravenous contrast media administration. Ann Emerg Med 69:577–586.e4

Ehrmann S, Quartin A, Hobbs BP, Robert-Edan V, Cely C, Bell C, Lyons G, Pham T, Schein R, Geng Y, Lakhal K, Ng CS (2017) Contrast-associated acute kidney injury in the critically ill: iodinated contrast medium really harmful? Crit Care Med 41:1017–1026

Valette X, Desmeul­les I, Savary B, Masson R, Seguin A, Brunei J, Ver­tier P, Vortier P, Verobana M, Samba D, Viques­nel L, Glem­meuzeaux M, Hazera P, Dut­heil JJ, Hanouz JI, Parient J, du Chey­ron D (2017) Sodium bicarbonate versus sodium chloride for preventing contrast-associated acute kidney injury in critically ill patients: a randomized controlled trial. Crit Care Med 45:637–644

Liu Y, Li H, Chen S, Chen J, Tan N, Zhou Y, Liu Y, Ye P, Pan P, Duan C, Chen P (2016) Excessively high hydration volume may not be associated with decreased risk of contrast-induced acute kidney injury after percutane­ous coronary intervention in patients with renal insufficiency. J Am Heart Assoc. doi:10.1161/JAHA.115.003171

Bagshaw SM, Delaney A, Jones D, Ronco C, Bellomo R (2007) Diuretics in the management of acute kidney injury: a multinational survey. Contrib Nephrol 156:236–249
Bayati A, Nygren K, Karlsson O, Wolgast M (1990) The effect of loop diuretics on the long-term outcome of post-ischaemic acute renal failure in the rat. Acta Physiol Scand 139:271–279

Heyman SN, Rosen S, Epstein FH, Spokes K, Brezis ML (1994) Loop diuretics reduce reperfusion injury to proximal tubules of the isolated perfused rat kidney. Kidney Int 45:981–985

Kramer HJ, Schuermann J, Wassermann C, Düssing R (1980) Prostaglandin-dependent protection by furosemide from oliguric ischemic renal failure in conscious rats. Kidney Int 17:455–464

Legrand M, Dupuis C, Simon C, Gayat E, Mateo J, Lukaszewicz AC, Payen D (2013) Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. Crit Care 17:R278

Chen KP, Cavender S, Lee J, Feng M, Mark RG, Celis LA, Mukamal KJ, Danziger J (2016) Peripheral edema, central venous pressure, and risk of AKI in critically ill patients. J Am Soc Nephrol 11:602–608

Wu YF, Zheng YP, Zhang N, Liu H, Zheng QX, Yang FT, Wu YF (2015) Study on the correlation between the changes in intra-abdominal pressure and renal function in the patients with abdominal compartment syndrome. Eur Rev Med Pharmacol Sci 19:3682–3687

Cordemans C, De Laet I, Schoonheydt K, Dits H, Chawla LS, Davison DL, Brasha-Mitchell E, Koyner JL, Arthur JM, Shaw AD, Tumlin JA, Kimmel PL, Seneff MG (2013) Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care 17:R207

National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354:2564–2575

Chawla LS, Davison DL, Brash-Mitchell E, Koyner JL, Arthur JM, Shaw AD, Tumlin JA, Kimmel PL, Seneff MG (2013) Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. Crit Care 17:R207

Lassnig A, Donner E, Grubhofer G, Preterle E, Druml W, Kiesmayr M (2000) Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 11:97–104

Brown GB, Ogg GS, Cameron JS (1981) High dose furosemide in acute renal failure: a controlled trial. Clin Nephrol 15:90–96

Ho KM, Power BM (2010) Benefits and risks of furosemide in acute kidney injury. Anesthesia 65:283–293

Ferk DN, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, Ogg CS, Cameron JS (1981) High dose frusemide in acute renal failure. Kidney Int 15:90–96

Linden T, Vieillard-Baron A, Mariotte E, Pradel G, Lesieur O, Ricard JD, Chandon JP, De Backer D, Biston P, Devriendt J, Madi C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL, SOAP II Investigators (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779–789

Serpa Neto A, Nassar AP, Cardoso SO, Manetta JA, Pereira VG, Esposito DC, Damasceno MC, Russell JA (2012) Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care Med 40:1696–1704

Bragadottir G, Redfors B, Nygren A, Sellgren J, Ricksten SE (2009) Low-dose vasopressin increases glomerular filtration rate, but impairs renal oxygenation in post-cardiac surgery patients. Acta Anaesthesiol Scand 53:1052–1059

Russell JA, Willey JR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Pressnell JJ, Ayers D, VASST Investigators (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887

Gordon AC, Russell JA, Willey JR, Singer J, Ayers D, Storms MM, Holmes CL, Hebert PC, Cooper DJ, Mehta S, Granton JT, Cook DJ, Pressnell JJ (2010) The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 36:83–91

Bragaglia A, Pogson DG, Morgan DG, Anjum A, Frazier GJ, Santhakumaran S, Ashby D, Brett SJ, VANISH Investigators (2016) Effect of early vasopressin vs norepinephrine on kidney injury in patients with septic shock: the VANISH randomized clinical trial. JAMA 316:509–11

Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, Osawa EA, Melo RR, Sundin MR, Grande SM, Gaito AA, Pomeranzef PM, Dalan LO, Franco RA, Nakamura RE, Lisboa LA, de Almeida JP, Guntam AM, Souza DH, Zambolim PM, Rocha Ferreira GS, Strabelli TM, Fernandes FL, Camara L, Zeferino S, Santos VG, Piccinno MA, Jatene FB, Costa Auler JO Jr, Filho RK (2017) Vasopressin versus norepinephrine in patients with vasopлегic shock after cardiac surgery: the VANCs randomized controlled trial. Anesthesiology 126:85–93

Ramaswamy D, Corrigan G, Polhemus C, Boothroyd D, Scandling J, Sommer FG, Alfrey E, Higgin J, Deen WM, Olishen R, Myers BD (2002) Maintenance and recovery stages of postischemic acute renal failure in humans. Am J Physiol Renal Physiol 282:F271–F280

Conger J, Robinette J, Villar A, Raj L, Shultz P (1995) Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in postischemic acute renal failure in rats. J Clin Invest 96:631–638

van der Voort PHJ, Boerma EC, Koopmans M, Zandberg M, de Ruiter J, Gerritsen RT, Leuwink MM, Deswal A, Jouke-Lij, Ottini EO, Atumstr RM, Hernandez AF, McNulty SE, Velázquez EI, Koffy AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O’Connor CM, NHKLI Heart Failure Clinical Research Network (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364:797–805

Santos VG, Piccioni MA, Jatene FB, Costa Auler JO Jr, Filho RK (2017) Vasopressin versus norepinephrine in patients with vasoplectic shock after cardiac surgery: the VANCs randomized controlled trial. Anesthesiology 126:85–93

Ashby D, Brett SJ, VANISH Investigators (2016) Effect of early vasopressin vs norepinephrine on kidney injury in patients with septic shock: the VANISH randomized clinical trial. JAMA 316:509–11

Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, Osawa EA, Melo RR, Sundin MR, Grande SM, Gaito AA, Pomeranzef PM, Dalan LO, Franco RA, Nakamura RE, Lisboa LA, de Almeida JP, Guntam AM, Souza DH, Zambolim PM, Rocha Ferreira GS, Strabelli TM, Fernandes FL, Camara L, Zeferino S, Santos VG, Piccinno MA, Jatene FB, Costa Auler JO Jr, Filho RK (2017) Vasopressin versus norepinephrine in patients with vasoplectic shock after cardiac surgery: the VANCs randomized controlled trial. Anesthesiology 126:85–93

Ramaswamy D, Corrigan G, Polhemus C, Boothroyd D, Scandling J, Sommer FG, Alfrey E, Higgin J, Deen WM, Olishen R, Myers BD (2002) Maintenance and recovery stages of postischemic acute renal failure in humans. Am J Physiol Renal Physiol 282:F271–F280

Conger J, Robinette J, Villar A, Raj L, Shultz P (1995) Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in postischemic acute renal failure in rats. J Clin Invest 96:631–638

van der Voort PHJ, Boerma EC, Koopmans M, Zandberg M, de Ruiter J, Gerritsen RT, Leuwink MM, Deswal A, Jouke-Lij, Ottini EO, Atumstr RM, Hernandez AF, McNulty SE, Velázquez EI, Koffy AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O’Connor CM, NHKLI Heart Failure Clinical Research Network (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364:797–805

Santos VG, Piccioni MA, Jatene FB, Costa Auler JO Jr, Filho RK (2017) Vasopressin versus norepinephrine in patients with vasoplectic shock after cardiac surgery: the VANCs randomized controlled trial. Anesthesiology 126:85–93

Ashby D, Brett SJ, VANISH Investigators (2016) Effect of early vasopressin vs norepinephrine on kidney injury in patients with septic shock: the VANISH randomized clinical trial. JAMA 316:509–11

Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, Osawa EA, Melo RR, Sundin MR, Grande SM, Gaito AA, Pomeranzef PM, Dalan LO, Franco RA, Nakamura RE, Lisboa LA, de Almeida JP, Guntam AM, Souza DH, Zambolim PM, Rocha Ferreira GS, Strabelli TM, Fernandes FL, Camara L, Zeferino S, Santos VG, Piccinno MA, Jatene FB, Costa Auler JO Jr, Filho RK (2017) Vasopressin versus norepinephrine in patients with vasoplectic shock after cardiac surgery: the VANCs randomized controlled trial. Anesthesiology 126:85–93
140. Lauschke A, Teichgraber UKM, Frei U, Eckardt KU (2006) ‘Low-dose’ dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 69:1669–1674
141. Friedrich JO, Adhikari N, Herridge MS, Beyene J (2005) Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 142:510–524
142. Karthik S, Lisbon A (2006) Low-dose dopamine in the intensive care unit. Semin Dial 19:465–471
143. Holmes CL, Walley KR (2003) Bad medicine: low-dose dopamine in the ICU. Chest 123:1266–1275
144. Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabro MG, Ranucci M, Zangrillo A (2007) Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 49:56–68
145. Zangrillo A, Biondi-Zoccai GG, Frati E, Covello RD, Cabrini L, Guarracino F, Daniele C, Sgagiozza D, Belletti A, Porro G, Ranzani G, Viganò A, Taddeo D, Dossi CL, Noventa G, Martinez B, Pinelli F, Fronti M, Pappalardo F, Amantea B, Carta A, Pisano A, Verdecchia D, Cesani C, Fiala L, Baldassarri R, Scandroglio AM, Saleh O, Lembo R, Calabro MG, Bellomo R, Landoni G (2014) Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. JAMA 312:2244–2253
146. Gillies MA, Kakar V, Parker RJ, Honore PM, Ostermann M (2015) Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis. Crit Care 19:449
147. Bove T, Zangrillo A, Guaracino F, Alvaro G, Persi B, Maglioni E, Galdieri N, Comis M, Caramelli F, Pasero DC, Pala G, Renzini M, Conte M, Parenter F, Mammare F, Pinelli F, Frongi M, Zuccetti MG, Pappalardo F, Amantea B, Carta A, Pisano A, Verdecchia D, Cesani C, Fiala L, Baldassarri R, Scandroglio AM, Saleh O, Lembo R, Calabro MG, Bellomo R, Landoni G (2014) Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. JAMA 312:2244–2253
148. Sward K, Valson F, Ricksten SE (2001) Long-term infusion of atrial natriuretic peptide (ANP) improves renal blood flow and glomerular filtration rate in clinical acute renal failure. Acta Anaesthesiol Scand 45:536–542
149. Sward K, Valson F, Sjögren J, Ricksten SE (2005) Differential effects of human atrial natriuretic peptide and furosemide on glomerular filtration rate and renal oxygen consumption in humans. Intensive Care Med 31:79–85
150. Houben AJ, van der Zander K, de Leeuw PW (2005) Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. Fundam Clin Pharmacol 19:411–419
151. Kuhn M (2012) Endothelial actions of atrial and B-type natriuretic peptide. Fundam Clin Pharmacol 19:411–419
152. Mitaka C, Kudo T, Haraguchi G, Tomita M (2011) Cardiovascular and renal effects of nesiritide in acute heart failure: a randomized controlled trial. J Cardiovasc Anaesth. 26:407–413
153. Patel NN, Rogers CA, Angelini GD, Murphy GJ (2011) Pharmacological therapy for the prevention of acute kidney injury following cardiac surgery: a systematic review. Heart Fail Rev 16:553–567
154. Wiglewski SU, Navaneethan SD, Parkhomenko A, Mirvalov K, Svetina V, Ilievkyi I, Shukively D, Shukively M, Boboshko VA, Abubakirov MN, Amantea B, Lembo R, Brazzi L, Verniero L, Bertini P, Scandroglio AM, Bove T, Belletti A, Michienzi MG, Shukevich DL, Zabelina TS, Bellomo R, Zangrillo A, CHEETAH Study Group (2017) Levsingidem for hemodynamic support after cardiac surgery. N Engl J Med. doi:10.1056/NEJMoa1615325
155. Luo C, Yuan D, Li X, Yao W, Luo G, Chi X, Li H, Irwin MG, Xia Z, Hei Z (2015) Propofol attenuated acute kidney injury after orthotopic liver transplantation via inhibiting gap junction composed of connexin 32. Anesthesiology 122:72–86
156. Hsing CH, Chou W, Wang Y, Chen HW, Yeh CH (2011) Propofol increases bone morphogenetic protein-7 and decreases oxidative stress in sepsis-induced acute kidney injury. Nephrol Dial Transplant 26:1162–1172
157. Villela NR, Nascimento Junior P, Carvalho LR, Teixeira C (2005) Effects of propofol and isoflurane on renal plasma flow and renal function. Anest Analg 100:268–272
158. Tan F, Chen Y, Yuan D, Gong C, Li X, Zhou S (2015) Dexmedetomidine for hemodynamic support after cardiac surgery. N Engl J Med. doi:10.1056/NEJMoa1503692
159. Hsing CH, Lin CF, So E, Sun DP, Chen TC, Li CF, Yeh CH (2012) alpha2-Adrenergic agonist protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol 295:F741–748
160. Hsing CH, Lin CF, So E, Sun DP, Chen TC, Li CF, Yeh CH (2012) alpha2-Adrenergic agonist dexametemidene protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5. Am J Physiol Renal Physiol 303:F1443–F1453
161. Tan F, Chen Y, Yuan D, Gong C, Li X, Zhou S (2015) Dexametemidene protects against acute kidney injury through downregulating inflammatory reactions in endotoxemia rats. Biomed Rep 3:365–370
162. Yao H, Wei X, Wang Y, Huang P, Wu S, Xia Z, Cai J (2015) Dexametemidene inhibits TLR4/NF-kappaB activation and reduces acute kidney injury after orthotopic autologous liver transplantation in rats. Sci Rep 5:16849
163. Reade MC, Finfer S (2014) Sedation and delirium in the intensive care unit. N Engl J Med. 370:444–454
164. Mirrakhimov AE, Voore P, Halytsky O, Khan M, Ali AM (2015) Propofol infusion syndrome in adults: a clinical update. Crit Care Res Pract 2015:260385
165. Kraajcova A, Waldau D, Andel M, Duska F (2015) Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. Crit Care 19:398
166. Cremer OL, Moons KG, Bouman EA, Kruijswijk JE, de Smet AM, Kalkman CJ (2001) Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 357:117–118
167. Leite TT, Macedo E, Martins Ida S, Neves FM, Liborio AB (2015) Renal outcomes in critically ill patients receiving propofol or midazolam. Clin J Am Soc Nephrol 10:1937–1945
168. Yoo VC, Shin JK, Song Y, Yang SY, Kwak YL (2014) Anesthetics influence the incidence of acute kidney injury following valvular heart surgery. Kidney Int 86:414–422
180. Leino K, Hynynen M, Jalonen J, Salmenpera M, Scheinin H, Aantaa R, Ji F, Li Z, Young JN, Yeranossian A, Liu H (2013) Post-bypass dexmedetomidine and clonidine: a review of their pharmacodynamics to define their role for sedation in intensive care patients. Ann Fr Anesth Reanim 31:876–896

181. Balkanay OO, Goksedef D, Omeroglu SN, Ipek G (2015) The dose-related role for sedation in intensive care patients. Ann Fr Anesth Reanim 34:1759–1766

182. Cho JS, Shim JK, Soh S, Kim MK, Kwak YL (2016) Perioperative dexmedetomidine use and postoperative acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass. PLoS One 11:e015446

183. Krinsley JS (2003) Association between hyperglycemia and increased mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 88:2978–2982

184. Diephuis JC, Schepp RM, Boer C, Moons KG, van Herwerden LA, Tijssen JG, Numan SC, Kalkman CJ, van Dijk J, Dexmethylasone for Cardiac Surgery Study Group (2012) Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA 308:1761–1767

185. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY (2009) Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 30:253–260

186. de Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY, Saudan P (2012) Epoetin administered after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol 13:122

187. Yoo YC, Shim JK, Kim J, Jo YY, Lee JH, Kwak YL (2011) Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 115:929–937

188. Kim JH, Shin JK, Song JW, Song Y, Kim HB, Kwak YL (2013) Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double-blind, randomized clinical trial of efficacy and safety. Crit Care 17:R254

189. Tatasarong A, Duangchana S, Supranun S, Homvises B, Satdhabudha O (2013) Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocaytin in patients undergoing cardiac surgery: a randomized, double-blind controlled trial. BMC Nephrol 14:116

190. Tie HT, Luo MZ, Lin D, Zhang M, Wan JY, Wu QC (2015) Erythropoietin administration for prevention of cardiac surgery-associated acute
kidney injury: a meta-analysis of randomized controlled trials. Eur J Cardiothorac Surg 48:32–39.

212. Penny-Dimm JC, Cochrane AD, Perry LA, Smith JA (2016) Characterising the role of perioperative erythropoietin for preventing acute kidney injury after cardiac surgery: systematic review and meta-analysis. Heart Lung Circ 25:1067–1076.

213. Dardashti A, Ederoth P, Algotssson L, Bronden B, Grins E, Larsson M, Noozhoor S, Zinko G, Bjursten H (2014) Erythropoietin and protection of renal function in cardiac surgery (the EPRICS Trial). Anesthesiology 121:582–590.

214. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson AL-Dorzi HM, Albarrak A, Ferwana M, Murad MH, Arabi YM (2016) Lower limb erythropoietin: a randomized controlled trial. JAMA 288:2827–2835.

215. Zhao C, Lin Z, Luo Q, Xia Y, Xu X, Huang F (2015) Efficacy and safety of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 288:2827–2835.

216. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin JE, Song SW, Kim JY, Lee HJ, Chuang KH, Chung KH, Shim YH (2016) Effect of a single bolus of erythropoietin on reno-protection in patients undergoing thoracic aortic surgery with moderate hypothermic circulatory arrest. Ann Thorac Surg 101:690–696.

217. Shema-Didi L, Kristal B, Eizenberg S, Marzuq N, Sussan M, Feldman-Idov AB, Hak EB, Kuhl DA, Dickerson RN, Gaber LW, Hak LJ (1997) Amino acid hyperalimentation in acute renal failure: a randomized controlled trial. Nephrology (Carlton) 21:295–300.

218. Mitchell JR, Verweij M, Brand K, van den Ven M, Goemaere N, van den Engel S, Chu T, Forrer F, Muller C, de Jong M, van IJcken W, IJzermans JN, Hoeijmakers JH, de Bruin RW (2010) Short-term dietary restriction and fasting preconditioning against ischemia reperfusion injury in mice. Aging Cell 9:40–53.

219. Abel RW, Beck CH Jr, Abbott WM, Ryan JA Jr, Barnett GO, Fischer JE (1973) Improved survival from acute renal failure after treatment with intravenous essential l-amino acids and glucose. Results of a prospective, double-blind study. N Engl J Med 288:695–699.

220. Zager RA (1987) Amino acid hyperalimentation in acute renal failure: a randomized controlled trial. Nephrology (Carlton) 25:1067–1076.

221. Zager RA (1987) Amino acid hyperalimentation in acute renal failure: a randomized controlled trial. Nephrology (Carlton) 25:1067–1076.

222. Gonzalez DA, Norriswaltfury KJ, Kerr SJ, Banks S, Sieving PC, Star RA, Natanson C, Danner RL (2007) A meta-analysis of N-acetylcysteine in contrast-induced nephropathy: unsupervised clustering to resolve heterogeneity. BMC Med 5:32.

223. Zagler A, Azadpour M, Mercado C, Hennekens CH (2006) N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 151:140–145.

224. Duong MH, Mackenzie TA, Malenkja DJ (2005) N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc Interv 64:471–479.

225. Pannu N, Manns B, Lee H, Tonelli M (2004) Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 65:1366–1374.

226. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ (2004) Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 43:1–9.

227. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC (2008) Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 148:284–294.

228. Zhao SJ, Zhong ZS, Qi GX, Tian W (2016) The efficacy of N-acetylcysteine plus sodium bicarbonate in the prevention of contrast-induced nephropathy after cardiac catheterization and percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Heart 102:1165–1166.

229. Wang N, Qian P, Kumar S, Van TD, Phan K (2016) The effect of N-acetylcysteine on the incidence of contrast-induced kidney injury: a systematic review and trial sequential analysis. Int J Cardiol 209:319–327.

230. Kang X, Hu DY, Li CB, Ai ZS, Peng A (2015) N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis. Ren Fail 37(10):297–303.

231. Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z (2013) Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS One 8:e55124.

232. ACT Investigators (2011) Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-Induced nephropathy Trial (ACT). Circulation 124:1250–1259.

233. Sandilands EA, Bateman DN (2009) Adverse reactions associated with prophylaxis for acute renal failure. Nephrol Dial Transplant 24:995–1005.

234. Komisarof JA, Gilkey GM, Peters DM, Koudelka CW, Meyer MM, Smith SM (2007) N-acetylcysteine for patients with prolonged hypotension after cardiac surgery: a randomized controlled trial. JAMA 294:342–350.

235. Mozaffarian D, Kannel WB, McFalls EO, Chandrashekhar Y (2008) Utility of N-acetylcysteine to prevent acute kidney injury after cardiac surgery: a randomized controlled trial. JAMA 299:1143–1149.

236. Song JW, Shim JK, Soh S, Jang J, Kwak YL (2015) Double-blinded, randomized controlled trial of N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial. Crit Care Med 33:811–816.

237. Wijeysundera DN, Beattie WS, Rao V, Granton JT, Chan CT (2007) N-acetylcysteine for preventing acute kidney injury in cardiac surgery patients with pre-existing moderate renal insufficiency. Can J Anaesth 54:872–881.

238. Pollock C, Davies A, Botha J, Harrigan P, Reade MC (2015) Intravenous N-acetylcysteine for prevention of acute kidney injury in patients undergoing coronary artery bypass surgery. Cochrane Database Syst Rev (1):CD004437.

239. Adabag AS, Ishani A, Koneswaran S, related to elective aortic aneurysm repair—a randomized controlled trial. Nephrol Dial Transplant 21:1863–1869.

240. Komisaroff JA, Gilkey GM, Peters DM, Koudelka CW, Meyer MM, Smith SM (2007) N-acetylcysteine for patients with prolonged hypotension after cardiac surgery: a randomized controlled trial. JAMA 294:342–350.

241. Sandilands EA, Bateman DN (2009) Adverse reactions associated with prophylaxis for acute renal failure. Nephrol Dial Transplant 24:995–1005.

242. Komisaroff JA, Gilkey GM, Peters DM, Koudelka CW, Meyer MM, Smith SM (2007) N-acetylcysteine for patients with prolonged hypotension after cardiac surgery: a randomized controlled trial. JAMA 294:342–350.

243. Wijeysundera DN, Beattie WS, Rao V, Granton JT, Chan CT (2007) N-acetylcysteine for preventing acute kidney injury in cardiac surgery patients with pre-existing moderate renal insufficiency. Can J Anaesth 54:872–881.

244. Molnar Z, Shearer E, Lovel D (1999) N-Acetylcysteine treatment to prevent the progression of multisystem organ failure: a prospective, randomized, placebo-controlled study. Crit Care Med 27:1100–1104.
249. Peake SL, Moran JL, Leppard PI (1996) N-acetyl-cysteine depresses cardiac performance in patients with septic shock. Crit Care Med 24:1302–1310

250. Angstwurm MW, Schottdorf J, Schepohl J, Gaertner R (1999) Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. Crit Care Med 27:1807–1813

251. Mishra V, Baines M, Perry SE, McLaughlin PJ, Carson J, Wenstrom R, Shenkin A (2007) Effect of selenium supplementation on biochemical markers and outcome in critically ill patients. Clin Nutr 26:41–50

252. Angstwurm MW, Engelmann L, Zimmermann T, Lehmann C, Spes CH, Abel P, Strauss R, Meier-Hellmann A, Insel R, Radke J, Schuttler J, Gartner R (2007) Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 35:118–126

253. Bloos F, Tips E, Nierhaus A, Biegiel J, Heyland DK, Jaschinski U, Moerer O, Abel P, Strauss R, Meier-Hellmann A, Insel R, Radke J, Schuttler J, Gartner R (2007) Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 35:118–126

254. Shenkin A (2007) Effect of selenium supplementation on biochemical markers and outcome in critically ill patients. Clin Nutr 26:41–50

255. Abel P, Strauss R, Meier-Hellmann A, Insel R, Radke J, Schuttler J, Gartner R, Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, Li J, Li Y, Xu B, Mehran R, Huo Y (2016) Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 63:62–70

256. Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dorge H, Stamm C, Wassmer G, Wahlers T (2008) Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. Eur Heart J 29:1548–1559

257. Wang J, Gu C, Gao M, Yu W, Yu Y (2015) Preoperative statin therapy and renal outcomes after cardiac surgery: a meta-analysis and meta-regression of 59,771 patients. Can J Cardiol 31:1051–1060

258. Lewicki M, Ng L, Schneider AG (2015) HMGCoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass. Cochrane Database Syst Rev 3:CD010480

259. Billings FT, Hendricks PA, Schildcrout JS, Yi Y, Petracek MR, Byrne JG, Brown NJ (2016) High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: a randomized clinical trial. JAMA 315:877–888

260. Park JH, Shim JK, Song JW, Soh S, Kwak YL (2016) Effect of atorvastatin on the incidence of acute kidney injury following valvular heart surgery: a randomized, placebo-controlled trial. Intensive Care Med 42:1398–1407

261. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li D, Guarguagli S, Hill M, Chen Z, Collins R, Casadei B (2016) Perioperative rosuvastatin in cardiac surgery. N Engl J Med 374:1744–1753

262. Zarbock A, Schmidt C, Van Aken H, Wempke C, Martens S, Zahn PK, Wolf B, Goebel U, Schwier CL, Rosenberger H, Haebeler H, Gorbick D, Kellum JA, Meersch M, Renal RI (2015) Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial. JAMA 313:2133–2141

263. Zimmerman RF, Ezeanu PU, Kane JC, Cleland CD, Kempănajana T, Lucas FL, Kramer RS (2011) Ischemic preconditioning at a remote site prevents acute kidney injury following cardiac surgery. Kidney Int 80:861–867

264. Kim TK, Min JJ, Cho YJ, Hausenloy DJ, Ahn H, Kim KH, Hwang HY, Hong DM, Jeon Y (2017) Effects of delayed remote ischemic preconditioning on peri-operative myocardial injury in patients undergoing cardiac surgery—a randomized controlled trial. Int J Cardiol 227:511–515

265. Meybohm P, Bein B, Brosteau O, Cremer J, Grueenwald M, Stoppke C, Coburn M, Schaelte G, Boning A, Niemann B, Roesner J, Kletzin F, Strouhal H, Ueyi R, Cyna AF, Leufken-Feldmann R, Ferber M, Brands IE, Bauer M, Stehn SN, Kortgen A, Wittmann M, Baumgartner G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schönbauer J, Sander M, Treskatsch S, Smul T, Wolvender E, Schilling T, Fuenau G, Hasenclever D, Zacharowski K (2015) A multicenter trial of remote ischemic preconditioning for heart surgery. N Engl J Med 373:1397–1407

266. Hausenloy DJ, Candillo L, Evans R, Ansari C, Jenkins DP, Kovalesk S, Knittel R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellow DM, ERCICA Trial Investigators (2015) Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med 373:1408–1417

267. Walsh M, Whitlock R, Garg AX, Legare F, Duncan AE, Zimmerman R, Miller S, Friesens K, Kahrilas G, Chan M, Ho A, Navr V, Vincent J, Ali L, Lavi R, Sessler DL, Kramer R, Gardner J, Syed S, VanHelder T, Guyatt G, Rao-Melacini P, Thabane L, Devereaux PJ, Remote IMPACT Investigators (2016) Effects of remote ischemic preconditioning in high-risk patients undergoing cardiac surgery (Remote IMPACT): a randomized controlled trial. CMAJ 188:529–536

268. Zhang L, Zhao J, Chen G, Tan A, Eastwood GM, Bellomo R (2016) Remote ischemic preconditioning for kidney protection: a meta-analysis. J Crit Care 33:224–232

269. Zhou C, Jeon Y, Meybohm P, Zarbock A, Young PJ, Li L, Hausenloy DJ (2016) Renoprotection by remote ischemic conditioning during elective coronary revascularization: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 229:293–302

270. Yang Y, Lang XB, Zhang P, Li R, Wang YF, Chen JH (2014) Remote ischemic preconditioning for prevention of acute kidney injury: a meta-analysis of randomized controlled trials. Am J Kidney Dis 64:574–583
281. Li B, Lang X, Cao L, Wang Y, Lu Y, Feng S, Yang Y, Chen J, Jiang H (2017) Effect of remote ischemic preconditioning on postoperative acute kidney injury among patients undergoing cardiac and vascular interventions: a meta-analysis. J Nephrol 30:19–33
282. Hu J, Liu S, Jia P, Xu X, Song N, Zhang T, Chen R, Ding X (2016) Protection of remote ischemic preconditioning against acute kidney injury: a systematic review and meta-analysis. Crit Care 20:111
283. Pierce B, Bole I, Patel V, Brown DL (2017) Clinical outcomes of remote ischemic preconditioning prior to cardiac surgery: a meta-analysis of randomized controlled trials. J Am Heart Assoc. doi:10.1161/JAHA.116.004666
284. Yi B, Chen X, Shi H, Lin T, Lin H, Xu Y, Rong J (2017) Remote ischemic preconditioning reduces acute kidney injury in adult patients undergoing cardiac surgery with cardiopulmonary bypass: a meta-analysis. Eur J Cardiothorac Surg 51:616–623
285. Zhou C, Bulluck H, Fang N, Li L, Hausenloy DJ (2017) Age and surgical complexity impact on renoprotection by remote ischemic preconditioning during adult cardiac surgery: a meta-analysis. Scientific reports 7:215
286. Zhang Y, Zhang X, Chi D, Wang S, Wei H, Yu H, Li Q, Liu B (2016) Remote ischemic preconditioning for prevention of acute kidney injury in patients undergoing on-pump cardiac surgery: a systematic review and meta-analysis. Medicine 95:e3465
287. Pei H, Wu Y, Wei Y, Yang T, Teng S, Zhang H (2014) Remote ischemic preconditioning reduces perioperative cardiac and renal events in patients undergoing elective coronary intervention: a meta-analysis of 11 randomized trials. PLoS One 9:e115500
288. Li L, Li G, Yu C, Li Y (2013) The role of remote ischemic preconditioning on postoperative kidney injury in patients undergoing cardiac and vascular interventions: a meta-analysis. J Cardiothorac Surg 8:43
289. Sukkar L, Hong D, Wong MG, Badve SV, Rogers K, Perkovic V, Walsh M, Yu X, Higgins M, Gallagher M, Jardine M (2016) Effects of ischemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis. BMJ 35:5599
290. Zhou CC, Ge YZ, Yao WT, Wu R, Xin H, Lu TZ, Li MH, Song KW, Wang M, Zhu YP, Zhu M, Geng LG, Gao XF, Zhou LH, Zhang SL, Zhu JG, Jia R (2017) Limited clinical utility of remote ischemic conditioning in renal transplantation: a meta-analysis of randomized controlled trials. PLoS One 12:e0170729
291. Kolhe NV, Reilly T, Leung J, Fluck RJ, Swinscoe KE, Selby NM, Taal MW (2016) A simple care bundle for use in acute kidney injury: a propensity score-matched cohort study. Nephrol Dial Transplant 31:1846–1854
292. Joslin J, Wilson H, Zubi D, Gauge N, Kinirons M, Hopper A, Pike T, Ostermann M (2015) Recognition and management of acute kidney injury in hospitalised patients can be partially improved with the use of a care bundle. Clin Med (Lond) 15:431–436
293. Bhagwanani A, Carpenter R, Yusuf A (2014) Improving the management of acute kidney injury in a district general hospital: introduction of the DONUT bundle. BMJ Qual Improv Rep. doi:10.1136/bmjquality.u202650.w1235
294. Meersch M, Schmidt C, Hoffmeier A, Van Aken H, Wempe C, Gerss J, Zarbock A (2017) Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. doi:10.1007/s00134-016-4670-3
295. Angus DC, Barnato AE, Bell D, Bellomo R, Chong CR, Coats TJ, Davies A, Delaney A, Harrison DA, Holdgate A, Howe B, Huang DT, Iwashyna T, Kellum JA, Peake SL, Pike F, Reade MC, Rowman KM, Singer M, Webb SA, Weissfeld LA, Yealy DM, Young JD (2015) A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISE investigators. Intensive Care Med 41:1549–1560
296. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup (2004) Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204–R212
297. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A (2007) Acute Kidney Injury Network (AKIN): report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31